Abeona Therapeutics Inc (ABEO) Expected to Post Earnings of -$0.29 Per Share

Equities analysts expect that Abeona Therapeutics Inc (NASDAQ:ABEO) will report earnings of ($0.29) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.19). Abeona Therapeutics reported earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year-over-year growth rate of 52.6%. The company is expected to announce its next earnings report on Friday, March 15th.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.16) to ($0.74). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.66) to ($0.82). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, November 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11). The firm had revenue of $1.71 million during the quarter, compared to analyst estimates of $1.02 million. Abeona Therapeutics had a negative net margin of 843.14% and a negative return on equity of 27.69%.

ABEO has been the topic of a number of recent analyst reports. Maxim Group restated a “buy” rating and issued a $35.00 price target on shares of Abeona Therapeutics in a research report on Friday, August 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Saturday, August 11th. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Finally, ValuEngine lowered shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $26.78.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Abeona Therapeutics by 1.4% in the third quarter. FMR LLC now owns 7,191,492 shares of the biopharmaceutical company’s stock valued at $92,051,000 after buying an additional 97,185 shares during the period. BlackRock Inc. lifted its holdings in Abeona Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock valued at $28,418,000 after buying an additional 35,610 shares during the period. Vanguard Group Inc. lifted its holdings in Abeona Therapeutics by 7.6% in the third quarter. Vanguard Group Inc. now owns 1,539,008 shares of the biopharmaceutical company’s stock valued at $19,699,000 after buying an additional 108,333 shares during the period. Millennium Management LLC lifted its holdings in Abeona Therapeutics by 5.3% in the second quarter. Millennium Management LLC now owns 964,839 shares of the biopharmaceutical company’s stock valued at $15,437,000 after buying an additional 48,583 shares during the period. Finally, Nexthera Capital LP lifted its holdings in Abeona Therapeutics by 35.6% in the third quarter. Nexthera Capital LP now owns 849,979 shares of the biopharmaceutical company’s stock valued at $10,880,000 after buying an additional 223,175 shares during the period. Institutional investors and hedge funds own 75.11% of the company’s stock.

NASDAQ:ABEO traded up $0.39 on Friday, reaching $8.20. The stock had a trading volume of 649,696 shares, compared to its average volume of 613,350. The firm has a market cap of $374.45 million, a PE ratio of -12.42 and a beta of 1.77. Abeona Therapeutics has a 1-year low of $6.94 and a 1-year high of $22.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: How is inflation measured?

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply